ntrx-07-sdd
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 10, 2019 (NCT04375436)
Timeline
Indications
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07058688 | Phase 2 | Mar 1, 2025 | NeuroTherapia, Inc. |
| NCT06194552 | Phase 1 | Sep 6, 2022 | NeuroTherapia, Inc. |
| NCT04375436 | Phase 1 | Oct 10, 2019 | Integrium, NeuroTherapia, Inc., Orange County Research Center |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroTherapia, Inc. | For profit | 3 | 3 | 2 | 2019 |
| Integrium | For profit | 1 | 0 | 1 | 2019 |
| Orange County Research Center | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1